PINEBROOK, N.J.--(BUSINESS WIRE)--Alvogen, the multinational pharmaceuticals company, agreed in December 2013 to become the majority shareholder in Taiwanese Lotus Pharmaceuticals (“Lotus”) through a private placement of newly issued shares, acquiring up to 151 million shares in the company. The total transaction value will be approximately US$200 million (approx. NTD 6 billion). As a results of the transaction, Alvogen´s shareholding will be approximately 67% in Lotus.
Help employers find you! Check out all the jobs and post your resume.
